Treace Medical Concepts (NASDAQ:TMCI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Treace Medical Concepts (NASDAQ:TMCI) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other research analysts have also issued reports on the stock. Truist Financial dropped their price objective on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a report on Thursday, December 18th. UBS Group decreased their price target on shares of Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Wednesday, January 21st. Stifel Nicolaus reduced their price objective on shares of Treace Medical Concepts from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 7th. Finally, JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $5.00 target price (down from $8.00) on shares of Treace Medical Concepts in a research report on Friday, November 7th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $4.21.

Treace Medical Concepts Stock Down 2.2%

Shares of TMCI opened at $2.21 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.36 and a current ratio of 3.37. Treace Medical Concepts has a 52 week low of $2.02 and a 52 week high of $10.45. The stock has a market capitalization of $140.82 million, a price-to-earnings ratio of -2.76 and a beta of 0.74. The stock has a fifty day moving average of $2.57 and a 200-day moving average of $4.77.

Hedge Funds Weigh In On Treace Medical Concepts

Several hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP lifted its position in shares of Treace Medical Concepts by 212.5% during the 4th quarter. GSA Capital Partners LLP now owns 347,755 shares of the company’s stock valued at $852,000 after acquiring an additional 236,477 shares during the period. HighTower Advisors LLC acquired a new stake in Treace Medical Concepts in the fourth quarter worth $33,000. First Eagle Investment Management LLC increased its stake in Treace Medical Concepts by 18.1% in the fourth quarter. First Eagle Investment Management LLC now owns 1,462,983 shares of the company’s stock valued at $3,584,000 after purchasing an additional 224,088 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in shares of Treace Medical Concepts during the fourth quarter valued at about $1,445,000. Finally, Balance Wealth LLC acquired a new position in shares of Treace Medical Concepts during the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

About Treace Medical Concepts

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.